532 nm laser therapy for treatment-resistant plantar warts: a prospective, randomized, placebo-controlled clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037358

Enrollment

Registered

2025-07-23

Start date

2025-08-18

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B07

Interventions

Group 1: 532 nm LBO laser treatment

baseline therapy with salicylic acid solution. Patients are examined and treated every four weeks (visits 1-3). Data is collected using pre-prepared questionnaires, and macroscopic and microscopic pho

standard therapy with salicylic acid solution. Patients are examined and treated every four weeks (visits 1-3). Data is collected using pre-prepared questionnaires, and macroscopic and microscopic pho

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 18 years or older Exclusively plantar wart Treatment-resistant wart (at least one prior treatment method has been used, e.g. curettage, cryotherapy, topical application of 5-FU and/or salicylic acid; combinations are also possible) Wart duration of at least 6 months Index wart diameter = 1.5 cm Signed informed consent is available

Exclusion criteria

Exclusion criteria: Diabetes mellitus Current immunosuppressive therapy Autoimmune diseases Active cancer Pacemaker Non-compliance Pregnant or breastfeeding women Polyneuropathy Allergy to local anesthetics (mepivacaine) Allergy or intolerance to salicylic acid or salicylates (tincture) Renal insufficiency (contraindication for the use of salicylic acid–containing tincture)

Design outcomes

Primary

Measure	Time frame
Complete clearance of the index wart. This will be recorded during follow-up examinations (every 4 weeks; visits 1-3) and during the final examination (3 months after the wart has completely healed or at the latest 3 months after the 3rd visit). An observation period of approximately 6-12 months per patient is planned. Data will be collected using photographic documentation, including a micrograph taken under a reflected light microscope, as well as prepared questionnaires at each visit/examination.	—

Measure

Time frame

Complete clearance of the index wart. This will be recorded during follow-up examinations (every 4 weeks; visits 1-3) and during the final examination (3 months after the wart has completely healed or at the latest 3 months after the 3rd visit). An observation period of approximately 6-12 months per patient is planned. Data will be collected using photographic documentation, including a micrograph taken under a reflected light microscope, as well as prepared questionnaires at each visit/examination.

—

Secondary

Measure	Time frame
Partial clearance rate of the wart (more than 50%)	—

Countries

Germany

Contacts

Public ContactOzan Haase

Hautpartner - Gemeinschaftspraxis Dres. Krengel/Mrowka/Haase

kontakt@hautpartner.de+49 451 81551

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026